Results 191 to 200 of about 176,756 (350)

Epigallocatechin‐3‐Gallate Suppresses Glioma by Targeting Integrin αvβ3/FAK/ERK Signaling Axis and Matrix Metalloproteinases

Phytotherapy Research, EarlyView.
EGCG suppresses glioma progression by targeting integrin αvβ3/FAK/ERK signaling and inhibiting MMP‐2/MMP‐9‐mediated ECM degradation, thereby blocking proliferation, migration, invasion, and promoting apoptosis. ABSTRACT Epigallocatechin‐3‐gallate (EGCG), the most abundant and biologically active catechin in green tea, has been widely reported to ...
Rui Sun, Yonghan Pan, Ning Yang, Bing Kang, Hong Xiao, Xianglong Tang, Taiping Li, Mengjie Zhao   +7 more
wiley   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

The Multifaceted Role of Rad9 in the DNA Damage Response of Saccharomyces cerevisiae

Yeast, EarlyView.
ABSTRACT To maintain the integrity of the genome, cells have evolved a complex signalling system, termed the DNA damage response (DDR), which detects DNA damage and promotes DNA repair. To date, over 600 proteins have been identified that play an integral role in the DDR. RAD9, encoding a DDR mediator protein, was the prototypical DNA damage checkpoint
A. Kiely, F. O'Halloran, P. Young, N. F. Lowndes, M. Grenon, K. Finn   +5 more
wiley   +1 more source

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

, 2018
Li, Edward
openalex   +2 more sources

Figure S2 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

, 2023
Annalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio, Sara E. Bellomo, Matteo Benelli, Loris De Cecco, Dario Romagnoli, Enrico Berrino, Claudia Orrù, Salvatore Ribisi, Daniel Moya-Rull, Cristina Migliore, Daniela Conticelli, Irene M. Maina, Elisabetta Puliga, Violeta Serra, Benedetta Pellegrino, Alba Llop‐Guevara, Antonino Musolino, Salvatore Siena, Andrea Sartore‐Bianchi, Michele Prisciandaro, Federica Morano, Maria Antista, Uberto Fumagalli, Giovanni De Manzoni, Maurizio Degiuli, Gian Luca Baiocchi, Marco F. Amisano, Alessandro Ferrero, Caterina Marchiò, Simona Corso, Silvia Giordano   +32 more
openalex   +1 more source

Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer. [PDF]

J Ovarian Res
Ye L, Chen Y, Chen Y, Zhao Q, Cheng X, Wang X, Xu X, Guo W, Chen X, Ni J.   +9 more
europepmc   +1 more source

Use of First-Line PARP Inhibitors in Ovarian Cancer

, 2019
Ursula Hasler-Strub
openalex   +1 more source

Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

, 2023
Stephanie L. Wethington, Payal D. Shah, Lainie P. Martin, János L. Tanyi, Nawar Latif, Mark A. Morgan, Drew A. Torigian, Diego Rodriguez, Simon A. Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie−Ming Shih, Eric J. Brown, Wei‐Ting Hwang, Deborah K. Armstrong, Stéphanie Gaillard, Robert Giuntoli, Fiona Simpkins   +18 more
openalex   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

Four New Menadione Thioderivatives, Potential Antineoplastic Candidates: In Silico and PARP-1 Inhibition Studies. [PDF]

Molecules
Pérez Flores FJ, Vázquez-López LJ, Rivera Espejel AL, Nicolás-Vázquez MI, Saavedra-Leos MZ, Fajardo de la Rosa AA, Álvarez-Almazán S, Martínez J, Miranda Ruvalcaba R.   +8 more
europepmc   +1 more source